PATENT CLAIM ANALYSIS

Application Number: 15862011
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "314000"]

Abstract:
The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: or pharmaceutically acceptable salt thereof.

Claim (Index 16):
The method of  claim 14 , wherein the Crenolanib is Crenolanib Besylate, Crenolanib Phosphate, Crenolanib Lactate, Crenolanib Hydrochloride, Crenolanib Citrate, Crenolanib Acetate, Crenolanib Toluenesulphonate or Crenolanib Succinate.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 86.0
- Lexical Diversity: 1.5122
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15255912', '14026886', '14026778', '14671613', '10579586']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8285282240943455
- 35 USC 102 Novelty (BERT): 0.6523026354186264
- Combined Prediction Score: 0.8109056652267737
- Mean Citation Score: 486.59087199999993
- Max Citation Score: 648.9252299999997
- Similarity Product: 599.0084490960984

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test